Application of Existing and Emerging Biomarkers for Immuno-Oncology Across Tumor Types

Learn from the experts about current and emerging immuno-oncology biomarkers to guide selection of optimal cancer treatment across tumor types. Participate in the interactive CCO Webinar or watch the on-demand Webcast and download the slides. Listen to a podcast for answers to FAQs asked during the live Webinar.
John L. Marshall, MD
Program Director
Jamie E. Chaft, MD
Scot Niglio, MD

Downloadable Slidesets

Download this short summary slideset of key takeaways from a live CCO Webinar on the use of biomarkers to identify patients who may benefit from immune checkpoint therapy across various solid tumors.

John L. Marshall, MD
Program Director
Jamie E. Chaft, MD Scot Niglio, MD
Released: July 15, 2020

Download this slideset from John L. Marshall, MD to review key data on the use of MSI/MMR testing and immunotherapy for patients with GI cancers.

John L. Marshall, MD
Program Director
Released: July 9, 2020

Download this slideset from Scot Niglio, MD to see an overview of how IO biomarkers are currently used for patients with GU cancers, with key data on immunotherapy approaches for bladder cancer, RCC, and prostate cancer.

Scot Niglio, MD Released: July 9, 2020

Download this slideset from Jamie E. Chaft, MD to see a summary of key data on the use of immune checkpoint inhibitor therapy for patients with lung cancer, with information on when IO biomarkers are needed to select optimal therapy.

Jamie E. Chaft, MD Released: July 9, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue